Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study.
The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157).
With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with Keytruda continued to demonstrate a clinically meaningful and durable improvement in recurrence-free survival (RFS), the primary endpoint of the study, reducing the risk of recurrence or death by 49% compared with Keytruda alone.
mRNA-4157 (V940) in combination with Keytruda also continued to demonstrate a meaningful improvement in distant metastasis-free survival (DMFS), a key secondary endpoint of the study, compared with Keytruda alone, reducing the risk of developing distant metastasis or death by 62%.
The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) combined with Keytruda was 74.8%, compared to 55.6% for Keytruda alone, with the benefit observed across exploratory subgroups.
The exploratory endpoint of overall survival (OS) favored mRNA-4157 (V940) in combination with Keytruda compared to Keytruda alone, with a 2.5-year OS rate of 96.0% vs. 90.2%, respectively.
The safety profile with mRNA-4157 (V940) in combination with Keytruda remains consistent with the primary analysis.
Merck and Moderna have initiated Phase 3 trials evaluating mRNA-4157 (V940) in combination with Keytruda as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma and non-small cell lung cancer. Both trials are actively enrolling.
In 2024, Merck and Moderna also initiated a two-part Phase 2/3 trial evaluating mRNA-4157 in combination with Keytruda as neoadjuvant and adjuvant treatment in patients with resectable locally advanced Stage II-IV (M0) cutaneous squamous cell carcinoma.
Price Action: At the last check on Monday, MRK shares were up 2.49% at $128.66, and MRNA shares were up 4.62% at $149.11.
Photo by Lutsenko_Oleksandr on Shutterstock
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga?
This article Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.